Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Meiji Seika Pharma Co. Ltd.
Sponsor

Meiji Seika Pharma Co. Ltd.

4-16 Kyobashi 2-chome Chuo-ku, 104-8002

About the sponsor

Meiji Seika Pharma Co. Ltd. focuses on antibacterial therapy for serious infections caused by carbapenem-resistant Enterobacterales, with research centered on treatment options for difficult-to-manage bacterial disease.

  • Complicated urinary tract infection (cUTI)
  • Acute uncomplicated pyelonephritis (AP)
  • Carbapenem-resistant Enterobacterales (CRE)

The sponsor’s research activity includes clinical evaluation of combination antibacterial approaches in adult patients with resistant infections affecting the urinary tract and related systemic bacterial disease.

About Specializations

Meiji Seika Pharma Co. Ltd. runs clinical trials in conditions such as Urinary tract infection, Abdominal infection, Pneumonia bacterial, Pyelonephritis, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Abdominal infection+3

Not recruiting
Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Urinary tract infection+1

Not recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.